Search

Displaying results 3901 - 3910 of 10000 in total
  1. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results in … [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate

  2. Drug

    Influenza B virus B/Darwin/7/2019 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15709
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  3. Drug

    99mTc-14 F7 Mab

    go.drugbank.com/drugs/DB05867
    Experimental

    99mTc 14F7 Mab has strong anti tumor activity against myeloma cells in vivo.

  4. Drug

    Lorpiprazole

    go.drugbank.com/drugs/DB09195
    Approved

    Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.

  5. Target

    Prostaglandin E synthase 3

    go.drugbank.com/bio_entities/BE0002480
    TargetHumans

    Cytosolic prostaglandin synthase that catalyzes the oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2) (PubMed:10922363). Molecular chaperone that localizes to genomic response elements in a hormone-depende...

    Synonyms: Progesterone receptor complex p23
  6. Target

    Proteasome subunit alpha type-2

    go.drugbank.com/bio_entities/BE0003911
    TargetHumans

    Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. … This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex)

    Synonyms: Multicatalytic endopeptidase complex subunit C3
  7. Target

    Proteasome subunit beta type-7

    go.drugbank.com/bio_entities/BE0003920
    TargetHumans

    Within the 20S core complex, PSMB7 displays a trypsin-like activity … Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins.

    Synonyms: Multicatalytic endopeptidase complex chain Z
  8. Drug

    Tipapkinogene sovacivec

    go.drugbank.com/drugs/DB06239
    Investigational

  9. Drug

    Influenza A virus A/Tasmania/503/2020 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16726
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  10. Drug

    Influenza B virus B/Singapore/INFTT-16-0610/2016 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15507
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.